Meritage Homes Corporation Common Stock (NY:MTH)

64.47 -0.02 (-0.03%)

Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Meritage Homes Corporation Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Meritage Homes (MTH) Q1 2023 Earnings Call Transcript ↗

April 28, 2023

MTH earnings call for the period ending March 31, 2023.

Via The Motley Fool

What 7 Analyst Ratings Have To Say About Meritage Homes ↗

April 28, 2023

Via Benzinga

Homebuilder Sentiment Surges Despite Housing Market Challenges ↗

April 27, 2023

Despite a constrained national housing market, homebuilder sentiment is on the rise, and so are the stock prices of most homebuilders.

Via Benzinga

D.R. Horton Earnings Should Tumble, But DHI Stock, Rival Homebuilders In Buy Zones ↗

April 19, 2023

Mortgage rates have pulled back after a spike last year hit housing.

Via Investor's Business Daily

Can AI Pick Stocks? ChatGPT Says Yes. (And Gives 13 Favorites!) ↗

April 18, 2023

The latest version of ChatGPT, GPT-4, offers significant advantages over the previous version. However, some issues persist with the AI chatbot.

Via InvestorPlace

5 Analysts Have This to Say About Meritage Homes ↗

April 12, 2023

Via Benzinga

Expert Ratings for Meritage Homes ↗

March 06, 2023

Via Benzinga

Meritage Homes Initiates Quarterly Dividend ↗

February 17, 2023

Via Benzinga

Meritage Homes (MTH) Q4 2022 Earnings Call Transcript ↗

February 02, 2023

MTH earnings call for the period ending December 31, 2022.

Via The Motley Fool

Meritage Homes Corp. (NYSE: MTH) Highlighted for Surprising Price Action

April 18, 2023

Via Investor Brand Network

This Analyst With 81% Accuracy Rate Sees More Than 20% Downside In CarMax - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts ↗

April 17, 2023

US stocks closed lower on Friday, with the Dow Jones dropping more than 100 points during the session.

Via Benzinga

This Market-Beating Industry Is in a Recession: 2 Stocks to Buy Before the Recovery ↗

April 16, 2023

Home sales have fallen sharply from the 2020-2021 peak and prices are starting to fall, too. But there are still ample opportunities for investors.

Via The Motley Fool

4 Top Value Stock ETFs for Long-Term Wealth Building ↗

March 19, 2023

It could be value's time to shine for the first time in years.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023 ↗

March 06, 2023

Via Benzinga

Earnings Preview: Meritage Homes ↗

January 31, 2023

Via Benzinga

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

5 Earnings Charts At 52-Week Highs ↗

January 31, 2023

Via Talk Markets

Homebuilder Stocks Soar Following Positive Market Data: What You Need To Know ↗

January 30, 2023

Homebuilder sentiment increased in January for the first time in a year after declining for 12 straight months, triggering a rally in homebuilder stocks. What Happened: Recent data issued by the...

Via Benzinga

$1000 Invested In Meritage Homes 15 Years Ago Would Be Worth This Much Today ↗

January 23, 2023

Via Benzinga

Meritage Homes (MTH) Q3 2022 Earnings Call Transcript ↗

October 27, 2022

MTH earnings call for the period ending September 30, 2022.

Via The Motley Fool

Meritage Homes: Q3 Earnings Insights ↗

October 26, 2022

Meritage Homes (NYSE:MTH) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:30 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 1, 2023 ↗

February 01, 2023

Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.

Via Benzinga

Expert Ratings for Meritage Homes ↗

October 12, 2022

Within the last quarter, Meritage Homes (NYSE:MTH) has observed the following analyst ratings:

Via Benzinga

KB Home Earnings Due With Homebuilder Outlook Key After Mortgage Rate Shock ↗

January 10, 2023

KBH stock and its peers have rebounded on hopes for brighter days ahead.

Via Investor's Business Daily

LGI Homes Stock Shows Rising Price Performance With Jump To 85 RS Rating ↗

December 16, 2022

LGI Homes stock now meets the desired 80-plus Relative Strength Rating criteria, with an increase from 65 to 85 Friday.

Via Investor's Business Daily

5 Homebuilder Stocks to Buy for Bottom Fishing Investors ↗

December 16, 2022

If the 2023 economy isn't as bad as feared, today's prices on homebuilder stocks will look very cheap next Christmas.

Via InvestorPlace

Massively Misunderstood: The Mega-Trend That Makes This Homebuilder Stock Worth Buying ↗

November 27, 2022

The downturn in homebuying is a normal part of the cycle. Looking beyond the pause, the structural challenges with supply make this homebuilder very attractive to own.

Via The Motley Fool

Heska To $165? Plus BTIG Cuts PT On This Stock By 67% ↗

November 14, 2022

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at...

Via Benzinga

What 4 Analyst Ratings Have To Say About Meritage Homes ↗

October 12, 2022

Meritage Homes (NYSE:MTH) has observed the following analyst ratings within the last quarter:

Via Benzinga

Is It Time Buy The Dip In Homebuilder Stocks? KeyBanc Says Yes, Names Top Picks ↗

September 19, 2022

Homebuilder stocks have gotten crushed so far in 2022, but one Wall Street analyst said Monday now is the time for investors to buy the dip. The Analyst: KeyBanc analyst Kenneth Zener has issued the...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.